MDMA’s federal approval drama, briefly explained
MDMA looked like it was on a fast track for PTSD treatment. Now, an FDA committee is advising otherwise.
Today, an Federal Drug Administration advisory committee held a public hearing to weigh the evidence on MDMA therapy for post-traumatic stress disorder, casting a non-binding vote against approving the treatment — indicating strong odds that the FDA will follow suit in their official determination, and setting a handful of precedents for efforts to legalize other psychedelics that are close behind.